California Biopharma Shows Promising Phase 1 Data
Source: Jason Kolbert  (12/9/24)
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. More >

FDA Decision on Drug for Bone Marrow Due Early 2025
Source: Dr. Douglas Loe  (12/6/24)
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. More >

Drug Trial Shows Positive Interim Results for ALS Treatment
Source: Streetwise Reports  (12/6/24)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others. More >

Approval Sought in Japan for New Drug to Lower Cholesterol
Source: Dr. Joseph Pantginis  (12/3/24)
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report. More >

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Source: Streetwise Reports  (12/3/24)
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced." More >

Is This California Biopharma Co. In the Right Place at the Right Time?
Source: Dr. Jonathan Aschoff  (12/3/24)
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies. More >

Biotech Initiates Phase III Trial for Heart Disease Drug
Source: Streetwise Reports  (11/20/24)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock. More >

Analyst Says Biotech's Data Supports Advancement Into Phase III
Source: Dr. Douglas Loe  (11/19/24)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. More >

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory
Source: Streetwise Reports  (11/8/24)
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise. More >

Pharma Stock Has Significant Upside Potential, Analyst Says
Source: Dr. Joseph Pantginis  (11/4/24)
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note. More >

Biotech Shares Positive Phase I Data for Alzheimer's Treatment
Source: Dr. Douglas Loe  (10/31/24)
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%. More >

Mass. Biotech Shares Strong Q3 Results
Source: Dr. David Nierengarten  (10/29/24)
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note. More >

Boston Biotech Announces Novartis Collaboration
Source: Dr. Robert Driscoll  (10/28/24)
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note. More >

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates
Source: Andrew Fein  (10/23/24)
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch. More >

Silver Break Out Confirmed
Source: Ron Struthers  (10/22/24)
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell. More >

NY Biopharma Shares Promising Clinical Data
Source: Dr. Ram Selvaraju  (10/18/24)
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note. More >

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.
Source: Ed Arce  (10/9/24)
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers. More >

Mass. Biotech Receives FDA Approval
Source: Dr. Jonathan Aschoff  (10/7/24)
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note. More >

CT Biotech Ready for Clinical Milestones
Source: Jason Kolbert  (10/4/24)
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note. More >

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Source: Jason Kolbert  (10/3/24)
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. More >

New Jersey Biotech Reports Positive Survival Data
Source: Dr. Joseph Pantginis  (10/2/24)
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price. More >

California Biotech's Target Price 200% Higher Than Current
Source: Jason Kolbert  (9/30/24)
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients. More >

Target Price Raised on Biotech Co.
Source: Robert Burns  (9/25/24)
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company. More >

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment
Source: Jason Kolbert  (9/23/24)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note. More >

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine
Source: Streetwise Reports  (9/17/24)
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential. More >